TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical has announced positive interim results from its Phase III clinical study of culmerciclib, a CDK2/4/6 inhibitor, in combination with fulvestrant for the first-line treatment of HR+/HER2-advanced breast cancer. The study, presented at the ESMO Congress 2025, demonstrated significant efficacy in delaying disease progression and improving response rates compared to the control group, with manageable safety profiles. These results position culmerciclib as a potential best-in-class therapy, enhancing the company’s standing in the oncology sector and offering promising implications for stakeholders.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical is a company in the pharmaceutical industry, focusing on innovative drug development. It specializes in creating advanced treatments for various medical conditions, with a strong emphasis on oncology and other critical therapeutic areas.
YTD Price Performance: 130.67%
Average Trading Volume: 151,738,660
Technical Sentiment Signal: Buy
Current Market Cap: HK$130.2B
See more data about 1177 stock on TipRanks’ Stock Analysis page.